# EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/egfr-tyrosine-kinase-inhibitor-tki-in-patients-with-advanced-non-small-cell-lung/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jianlin Xu,Bo Jin,Tianqing Chu,Xue Dong,Haitang Yang,Yanwei Zhang,Dan Wu,Yuqing Lou,Xueyan Zhang,Huiming Wang,Baohui Han |
| Citations | 94 |
| DOI | 10.1016/j.lungcan.2016.01.018 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2255412755 |
| PMID | 27133756 |
| Type | article |
| Year | 2016 |

## Paper authors

- [Jianlin Xu](https://scholariq.org/researchers/jianlin-xu/)

## Paper journal

- [Lung Cancer](https://scholariq.org/journals/lung-cancer/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.